Deciphering the Complexity of the Acute Leukemia Immunological Microenvironment with 3D Biology™ Technology

  • 12:00 pm - 1:00 pm (EDT)
Speakers: Doug Hinerfeld, Ph.D., Principal Product Application Scientist, NanoString Technologies; Sergio Rutella, M.D., Ph.D., Professor of Cancer Immunotherapy, John van Geest Cancer Research Centre, Nottingham Trent University

NanoString’s 3D Biology™ Technology, which enables simultaneous profiling of any combination of SNV, RNA, protein, and phospho-protein targets with as few as 5,000 cells or just two successive 5 micron FFPE slices, was used in this research study to collect comprehensive molecular profiles across the biological heterogeneity of childhood and adult AML, with the aim to identify new molecular targets for specific immunologic subtypes of AML.

Bone marrow (BM) specimens from 70 patients with non-promyelocytic AML were profiled on the nCounter® system. Ninety BM samples were analyzed with the nCounter PanCancer Immune Profiling Panel. The Vantage 3D DNA:RNA:Protein Heme alpha assay was used to dissect the intracellular signaling pathways that are activated in leukemia cell lines in response to IFN-g. The assay profiles 180 mRNA species involved in heme-oncology pathways, >38 total and phosphorylated proteins, and >124 single nucleotide variants relevant to hematological malignancies. BM biopsies from patients with AML were also analyzed with NanoString’s Digital Spatial Profiling Technology to investigate co-localization of CD8+ T cells and “actionable” negative immune checkpoints, such as PD-L1, and to characterize the quality of the BM-infiltrating T cells.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.